CERo Therapeutics Holdings, Inc.
CERO
$0.04
$0.008.70%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 605.40K | 500.00K | -- | -- | -- |
| Gross Profit | -605.40K | -500.00K | -- | -- | -- |
| SG&A Expenses | 10.65M | 9.64M | 10.29M | 10.05M | 10.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.93M | 17.50M | 17.04M | 16.75M | 16.20M |
| Operating Income | -19.93M | -17.50M | -17.04M | -16.75M | -16.20M |
| Income Before Tax | -19.92M | -14.71M | -14.08M | -11.11M | -8.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.92 | -14.71 | -14.08 | -11.11 | -8.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.92M | -14.71M | -14.08M | -11.11M | -8.30M |
| EBIT | -19.93M | -17.50M | -17.04M | -16.75M | -16.20M |
| EBITDA | -19.65M | -17.18M | -16.68M | -16.35M | -15.76M |
| EPS Basic | -107.45 | -151.28 | -312.40 | -314.48 | -344.85 |
| Normalized Basic EPS | -29.08 | -51.65 | -155.64 | -148.70 | -171.48 |
| EPS Diluted | -107.45 | -151.28 | -312.40 | -314.48 | -344.85 |
| Normalized Diluted EPS | -29.08 | -51.65 | -155.64 | -148.70 | -171.48 |
| Average Basic Shares Outstanding | 20.34M | 5.41M | 4.17M | 3.68M | 119.80K |
| Average Diluted Shares Outstanding | 20.34M | 5.41M | 4.17M | 3.72M | 157.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |